Build­ing on mo­men­tum from pos­i­tive di­a­betes da­ta, Zaf­gen scoops Bio­gen alum Priya Sing­hal as head of R&D

On the heels of some pos­i­tive mid-stage da­ta on its lead di­a­betes drug, Zaf­gen $ZFGN has brought in sea­soned biotech ex­ec Priya Sing­hal to steer­ing the next phase of its his­tor­i­cal­ly bumpy R&D jour­ney.

Most re­cent­ly a co-head of glob­al de­vel­op­ment at Bio­gen, Sing­hal’s re­sume shows a string of roles at sto­ried biotech shops like Ver­tex and Mil­len­ni­um. Re­port­ing to CEO Jef­frey Hat­field — the new chief brought in when Tom Hugh­es left the helm to take a CSO role — she has broad au­thor­i­ty over re­search, clin­i­cal and man­u­fac­tur­ing strat­e­gy and im­ple­men­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER